3 unknown, 1 completed. 4 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Unknown 3, Completed 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
Follow Hematologic Cancer: new trials by email Literature Review of Hematologic Cancer trials Research Report on Hematologic Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluate the Safety and Efficacy for Oral Mucositis Prevention of MIT-001 in Auto HSCT MIT-001, normal saline - Oral Mucositis, Lymphoma | Phase 2 | Unknown | MitoImmune Therapeutics | 60 | 2022-02-01 | 2024-05-29 |
| Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS Azacitidine, all trans retinoic acid - AML, MDS | Phase 2 / Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 180 | 2021-05-01 | 2022-01-03 |
| Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion) GLIDE - Hematologic Cancer, Relapse Leukemia | Phase 1 / Phase 2 | Unknown | Ciusss de L'Est de l'Île de Montréal | 20 | 2017-02-06 | 2017-12-06 |
| A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma elotuzumab, lenalidomide, dexamethasone oral - Hematologic Cancer | Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 101 | 2008-08-01 | 2018-01-10 |
Hematologic Neoplasms (4) · Multiple Myeloma (3) · Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Frailty (1) · Hodgkin Disease (1) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Stomatitis (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Neoplasms by Site (4) · Blood Protein Disorders (3) · Cardiovascular Diseases (3) · Hemorrhagic Disorders (3) · Hemostatic Disorders (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Lymphoproliferative Disorders (3) · Neoplasms, Plasma Cell (3) · Paraproteinemias (3) · Vascular Diseases (3)
Azacitidine (1) · Calcium Dobesilate (1) · Dexamethasone (1) · Lenalidomide (1) · Saline Solution (1) · Tretinoin (1) · elotuzumab (1)
AbbVie (prior sponsor, Abbott) (1) · Ciusss de L'Est de l'Île de Montréal (1) · MitoImmune Therapeutics (1) · The First Affiliated Hospital of Soochow University (1)
Canada (1) · China (1) · South Korea (1)
Denis-Claude Roy, MD PhD (1) · Han Yue, Ph.D (1) · Seok-Goo Cho, MD, PhD (1) · Silvy Lachance, MD (1)